TMEM119 and glioblastoma: Patients in the microglia-high cohort based on P2RY12 immunoreactivity had significantly longer survival times in glioblastoma, and although a similar trend was observed with TMEM119 microglial density, this was not statistically significant (Figure 6C and D).